There are few facilities such as NECSTGEN around the world: affordable, non-profit facilities that facilitate the product development of regenerative medical treatments – treatments that restore or replace diseased cells, tissues and organs. Regenerative medicine is considered a great promise in the pharmaceutical industry. The NECSTGEN is needed to test breakthroughs, develop them further and make them available to patients more quickly. The NECSTGEN, scheduled to open at the end of this year or early 2021, will help to further strengthen the Netherlands life science and biotech ecosystem.
The NautaDutilh team advising NECSTGEN consists of David van Dijk, Ramon Pop, David van Ee and Ruud Smits.